Sun Pharma is no longer under any court order that delays or restricts the launch of deuruxolitinib (Leqselvi) after receiving a favorable ruling from a New Jersey federal court, according to media reports.
The U.S. Food and Drug Administration (FDA) approved deuruxolitinib (Leqselvi, Sun Pharma) for adults with severe alopecia areata in 2024. This is the third Janus kinase (JAK) inhibitor approved for alopecia.
Incyte filed a lawsuit against Sun Pharma in 2024, stating that the drug infringed on a U.S. patent. The New Jersey federal court handed down an injunction blocking the drug’s rollout. The injunction, now lifted, prevented Sun from launching the medication until it won in court or the patent in question expires toward the end of 2026.
The preliminary injunction is no longer in effect, but the litigation between Incyte and Sun Pharma is ongoing. In its filing, Sun Pharma stated that it is “no longer under a court order that delays or restricts” the drug launch and will disclose its plans “in due course.” Stay tuned.
